Improve Medical Instruments Co., Ltd. (SHE:300030)
China · Delayed Price · Currency is CNY 6.92
+0.02 (0.29%)
Sep 30, 2026, 3:04 PM CST
SHE:300030 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,140 | 2,276 | 1,707 | 2,396 | 2,130 | 3,293 | |
Market Cap Growth | -9.78% | 33.33% | -28.77% | 12.48% | -35.30% | -13.30% |
Enterprise Value | 2,118 | 2,349 | 1,878 | 2,614 | 2,399 | 3,502 |
Last Close Price | 6.92 | 7.36 | 5.52 | 7.75 | 6.89 | 10.59 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 67.18 | 156.61 | - | - | - | 177.34 |
Forward PE | - | 29.05 | 29.05 | 29.05 | 29.05 | 29.05 |
PS Ratio | 4.55 | 4.68 | 2.94 | 3.72 | 3.00 | 4.12 |
PB Ratio | 3.15 | 3.47 | 2.65 | 3.14 | 2.60 | 3.20 |
P/TBV Ratio | 3.45 | 3.88 | 3.05 | 3.64 | 3.11 | 4.09 |
P/FCF Ratio | 17.44 | 26.53 | 55.86 | 66.19 | - | 32.70 |
P/OCF Ratio | 14.31 | 20.71 | 20.86 | 29.99 | 50.15 | 19.17 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.50 | 4.83 | 3.23 | 4.06 | 3.38 | 4.38 |
EV/EBITDA Ratio | 21.03 | 34.77 | 378.65 | 1351.88 | - | 47.61 |
EV/EBIT Ratio | 30.94 | 64.04 | - | - | - | 106.46 |
EV/FCF Ratio | 17.27 | 27.38 | 61.46 | 72.19 | - | 34.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.15 | 0.24 | 0.54 | 0.53 | 0.52 | 0.51 |
Debt / EBITDA Ratio | 0.99 | 2.18 | 35.24 | 34.44 | - | 6.09 |
Debt / FCF Ratio | 0.82 | 1.79 | 11.46 | 11.06 | - | 5.21 |
Net Debt / Equity Ratio | -0.07 | -0.01 | 0.16 | 0.21 | 0.25 | 0.17 |
Net Debt / EBITDA Ratio | -0.50 | -0.10 | 20.41 | 84.16 | -9.34 | 2.44 |
Net Debt / FCF Ratio | -0.41 | -0.08 | 3.31 | 4.49 | -12.99 | 1.78 |
Asset Turnover | 0.45 | 0.43 | 0.44 | 0.43 | 0.42 | 0.45 |
Inventory Turnover | 2.73 | 3.14 | 3.13 | 3.05 | 3.26 | 3.24 |
Quick Ratio | 1.10 | 1.03 | 0.90 | 0.85 | 0.84 | 0.97 |
Current Ratio | 1.51 | 1.33 | 1.15 | 1.10 | 1.13 | 1.25 |
Return on Equity (ROE) | 4.66% | 2.34% | -17.05% | -7.61% | -20.89% | 1.94% |
Return on Assets (ROA) | 4.05% | 2.02% | -1.40% | -1.40% | -2.25% | 1.15% |
Return on Invested Capital (ROIC) | 8.09% | 3.52% | -3.58% | -3.44% | -5.46% | 2.29% |
Return on Capital Employed (ROCE) | 9.40% | 5.20% | -4.10% | -4.10% | -6.60% | 2.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.41% | 0.64% | -6.91% | -2.64% | -9.31% | 0.56% |
FCF Yield | 5.73% | 3.77% | 1.79% | 1.51% | -0.73% | 3.06% |
Dividend Yield | - | - | - | - | - | 0.38% |
Payout Ratio | 12.42% | 37.83% | - | - | - | 167.72% |
Buyback Yield / Dilution | 11.79% | 6.34% | 1.82% | -1.99% | -0.12% | -0.93% |
Total Shareholder Return | 11.79% | 6.34% | 1.82% | -1.99% | -0.12% | -0.55% |